CARLO STELLA, CARMELO
 Distribuzione geografica
Continente #
NA - Nord America 6.474
EU - Europa 1.219
AS - Asia 687
AF - Africa 206
SA - Sud America 22
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 8.620
Nazione #
US - Stati Uniti d'America 6.417
SG - Singapore 398
FI - Finlandia 361
IE - Irlanda 248
CN - Cina 217
NG - Nigeria 205
DE - Germania 169
FR - Francia 121
NL - Olanda 70
IT - Italia 64
CA - Canada 57
GB - Regno Unito 52
SE - Svezia 29
CZ - Repubblica Ceca 28
RU - Federazione Russa 23
IL - Israele 20
BE - Belgio 17
TR - Turchia 16
CL - Cile 11
IN - India 11
IR - Iran 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AT - Austria 7
AR - Argentina 6
ES - Italia 6
RO - Romania 6
HK - Hong Kong 5
JP - Giappone 4
AU - Australia 3
BD - Bangladesh 3
CH - Svizzera 3
GR - Grecia 3
PE - Perù 3
PL - Polonia 3
UA - Ucraina 3
IQ - Iraq 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BR - Brasile 1
CO - Colombia 1
DK - Danimarca 1
HR - Croazia 1
KR - Corea 1
LU - Lussemburgo 1
NO - Norvegia 1
SA - Arabia Saudita 1
SI - Slovenia 1
ZA - Sudafrica 1
Totale 8.620
Città #
Wilmington 1.309
Chandler 1.266
San Mateo 502
Helsinki 359
Ann Arbor 332
Singapore 258
Dublin 247
Leawood 243
Lawrence 225
Princeton 225
Boardman 222
Shanghai 211
Benin City 205
Fairfield 124
Paris 112
New York 111
Woodbridge 95
Ashburn 94
Amsterdam 69
Toronto 53
London 48
Seattle 39
San Diego 31
Norwalk 27
Falls Church 26
Brno 23
Milan 19
Brussels 17
Los Angeles 16
Kocaeli 15
Phoenix 15
Santa Clara 15
Monmouth Junction 13
Gunzenhausen 12
Redmond 10
Abbiategrasso 9
Moscow 9
Munich 9
Nuremberg 8
Pune 8
Andover 6
Houston 6
Redwood City 6
Vienna 6
Berlin 5
Clearwater 5
Des Moines 5
Falkenstein 5
Munro 5
Novokuznetsk 5
Olomouc 5
Cambridge 4
Hanover 4
Sacramento 4
Saint Paul 4
Beijing 3
Cardiff 3
Cologne 3
Cupertino 3
Freiburg im Breisgau 3
Hong Kong 3
Las Vegas 3
Lima 3
Lissone 3
Montréal 3
Pozzuoli 3
Raleigh 3
Athens 2
Azzano Decimo 2
Canegrate 2
Eden Prairie 2
Genoa 2
Henderson 2
Jacksonville 2
La Canada Flintridge 2
Lappeenranta 2
Leipzig 2
St Petersburg 2
Stuttgart 2
Tappahannock 2
Voronezh 2
Adliswil 1
Apo 1
Auckland 1
Basra 1
Belovo 1
Bogotá 1
Brisbane 1
Buffalo 1
Büdelsdorf 1
Canberra 1
Central District 1
Chicago 1
Cinisello Balsamo 1
Clifton 1
Collingswood 1
Edison 1
Ferrara 1
Frankfurt am Main 1
Galway 1
Totale 6.789
Nome #
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 135
Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy 69
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 64
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 61
Detection of maternal progenitor cells in human umbilical cord blood by single-colony karyotyping 60
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade? 59
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis 58
Arachidonic acid induces c-jun gene expression in stromal cells stimulated by interleukin-1 and tumor necrosis factor-a: evidence for a tyrosine-kinase-dependent process 57
Radioimmunotherapy and secondary leukemia : a case report 57
INVITRO MEGAKARYOCYTOPOIESIS IN PATIENTS WITH HIV-RELATED THROMBOCYTOPENIC PURPURA 57
D Quantification of Tumor Vasculature in Lymphoma Xenografts in NOD/SCID Mice Allows to Detect Differences among Vascular-Targeted Therapies 57
Cell therapy: achievements and perspectives 56
EFFECT OF RECOMBINANT GAMMA-INTERFERON ON THE PROLIFERATIVE ACTIVITY OF CULTURED LEUKEMIC-CELLS 56
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 56
ACQUIRED CYCLIC THROMBOCYTOPENIATHROMBOCYTOSIS WITH PERIODIC DEFECT OF PLATELET-FUNCTION 56
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 56
UMBILICAL-CORD BLOOD AS A SOURCE OF HEMATOPOIETIC STEM-CELLS - FROM RESEARCH TO CLINIC 55
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K delta/gamma Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 53
T-lymphocyte function after retroviral-mediated thymidine kinase gene transfer and G418 selection 52
Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors 51
Stem cells and stem cell transplantation 51
B-cell reconstitution recapitulates B-cell lymphopoiesis following haploidentical BM transplantation and post-transplant CY 51
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes 51
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 51
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide 51
Expression and activation of SHC/MAP kinase pathway in primary acute myeloid leukemia blasts 50
A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogenic stem call transplantation from a HLA identical sibling 50
New reciprocal translocation t(5;10)(q33;q22) associated with atypical chronic myeloid leukemia 49
Primary refractory and early-relapsed Hodgkin's lymphoma : strategies for therapeutic targeting based on the tumour microenvironment 49
Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory Hodgkin Lymphoma 49
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma 49
AUTOLOGOUS TRANSPLANT FOR CHRONIC MYELOGENOUS LEUKEMIA USING MARROW TREATED EX-VIVO WITH MAFOSFAMIDE 49
Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction 49
EFFECT OF RECOMBINANT INTERFERON-ALPHA AND INTERFERON-GAMMA ON HUMAN-BONE MARROW DERIVED MEGAKARYOCYTIC PROGENITOR CELLS 48
BIOLOGICAL ASPECTS AND CLINICAL-APPLICATIONS OF LONG-TERM BONE-MARROW CULTURE - A MEETING REPORT 48
AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA 48
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 48
Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells 48
ESTABLISHMENT OF 2 EPSTEIN-BARR VIRUS NEGATIVE BURKITT CELL-LINES FROM A PATIENT WITH AIDS AND B-CELL LYMPHOMA 47
Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells 47
INVITRO AND INVIVO EFFECTS OF RECOMBINANT INTERFERON GAMMA ON THE GROWTH OF HEMATOPOIETIC PROGENITOR CELLS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROME 47
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma 47
Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma 46
Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome 46
CD34-POSITIVE CELLS - BIOLOGY AND CLINICAL RELEVANCE 45
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma : Final results of a multicenter phase II study 45
Arachidonic acid mediates interleukin-1 and tumor necrosis factor-alpha-induced activation sf the c-jun amino-terminal kinases in stromal cells 45
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia : evidence for premature aging of the myeloid compartment 45
Specific histone patterns and acetylase/deacetylase activity at the breakpoint-cluster region of the human MLL gene 45
Amifostine (WR-2721) selective protection against melphalan genotoxicity 45
Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation 44
Ex vivo expansion of hematopoietic cells and their clinical use 44
Autophagy as a pathogenic mechanism and drug target in lymphoproliferative disorders 44
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 44
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors. 44
Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation : results from a named patient program at four Italian centers 44
OLIGODEOXYNUCLEOTIDES ANTISENSE TO C-ABL SPECIFICALLY INHIBIT ENTRY INTO S-PHASE OF CD34(+) HEMATOPOIETIC-CELLS AND THEIR DIFFERENTIATION TO GRANULOCYTE-MACROPHAGE PROGENITORS 43
High-dose sequential chemotherapy and in vivo Rituximab-purged stem cell autografting in mantle cell lymphoma : a 10-year update of the R-HDS regimen 43
Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma : a single institution experience 43
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells 43
Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide 43
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma 43
NATURAL-KILLER-CELL REGENERATION AFTER TRANSPLANTATION WITH MAFOSFAMIDE PURGED AUTOLOGOUS BONE-MARROW 43
IN VITRO GROWTH OF BONE MARROW-DERIVED MULTIPOTENT AND LINEAGE-RESTRICTED HEMATOPOIETIC PROGENITOR CELLS IN MYELODYSPLASTIC SYNDROMES 43
Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine 42
Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice 42
The parallel between CD45 expression and extra-medullary evolution in aggressive myeloma with high serum lactate dehydrogenase 42
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 42
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 42
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (mTRAIL) 42
Biologic and phenotypic analysis of early hematopoietic progenitor cells in umbilical cord blood 42
Chronic myeloid leukemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation 42
EFFECTS OF RECOMBINANT ALPHA-INTERFERONS AND GAMMA-INTERFERONS ON THE INVITRO GROWTH OF CIRCULATING HEMATOPOIETIC PROGENITOR CELLS (CFU-GEMM, CFU-MK, BFU-E, AND CFU-GM) FROM PATIENTS WITH MYELOFIBROSIS WITH MYELOID METAPLASIA 41
The novel PI3K-ò inhibitor TGR-1202 enhances brentuximab vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. 41
Nonmyeloablative conditioning, unmanipulated haploidentical stem cell transplantation and post-infusion cyclophosphamide for advanced lymphomas 41
INTERFERONS AS BIOLOGIC MODULATORS OF HEMATOPOIETIC-CELL PROLIFERATION AND DIFFERENTIATION 41
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide 41
EFFECTS OF RECOMBINANT HUMAN H-SUBUNIT AND L-SUBUNIT FERRITINS ON INVITRO GROWTH OF HUMAN GRANULOCYTE MONOCYTE PROGENITORS 41
Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide 41
Stem cell manipulation: why and how performing peripheral blood progenitor cell purging 41
Effects of the tyrosine kinase inhibitor AG957 and an anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells 40
In vitro growth of mobilized peripheral blood progenitor cells is significantly enhanced by stem cell factor 40
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 40
Targeting Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Agonistic Receptors for Cancer Therapy 40
USE OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH LYMPHOID MALIGNANCIES TRANSPLANTED WITH UNPURGED OR ADJUSTED-DOSE MAFOSFAMIDE-PURGED AUTOLOGOUS MARROW 40
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 40
DEFECTIVE INVITRO GROWTH OF THE HEMATOPOIETIC PROGENITOR CELLS IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME 40
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B-cell lymphoma patients with relapsed and measurable disease : a pilot study 40
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 40
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 40
Primitive hematopoietic progenitors within mobilized blood are spared by uncontrolled rate freezing 40
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 40
Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma 40
STEM-CELLS AND STEM-CELL FACTOR(S) 40
Limited engraftment capacity of bone marrow-derived mesenchymal cells following T-cell-depleted hematopoietic stem cell transplantation 40
Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) 39
MicroRNA-127-3p controls murine hematopoietic stem cell maintenance by limiting differentiation 39
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 39
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients 39
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies : posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery 39
Totale 4.731
Categoria #
all - tutte 69.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.861


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.265 4 17 6 7 9 751 336 147 445 303 8 232
2021/20221.277 68 5 19 275 19 20 30 165 130 193 286 67
2022/20233.390 487 102 293 411 326 292 0 310 604 281 236 48
2023/20241.820 139 218 335 41 30 128 67 132 24 36 280 390
2024/202580 80 0 0 0 0 0 0 0 0 0 0 0
Totale 8.832